Literature DB >> 20167512

Long-term efficacy of valproate versus lamotrigine in treatment of idiopathic generalized epilepsies in children and adolescents.

Maria Mazurkiewicz-Bełdzińska1, Marta Szmuda, Agnieszka Matheisel.   

Abstract

PURPOSE: In order to estimate and compare the long-term effectiveness of lamotrigine (LTG) versus valproate (VPA) monotherapy in treatment of newly diagnosed idiopathic generalized epilepsies (IGE) the following study was performed.
METHODS: Medical records of 214 children and adolescents suffering from IGE were analyzed. 132 of them were on VPA monotherapy, 82 on LTG. The majority of patients had juvenile myoclonic epilepsy - 98, the rest: juvenile absence epilepsy - 32, childhood absence epilepsy - 53 and epilepsy with a tonic-clonic seizures on awakening - 12, others - 19. Mean age of the patients was 8.9 years (range 4-16 years). The mean time of treatment was 28 months, time of observation 40 months. In order to estimate retention rates and factors predicting successful treatment with LTG and VPA we used Kapplan-Meyer analysis and Gehan tests.
RESULTS: Data analysis showed significantly longer retention rates with VPA versus LTG treatment in overall rates as well in all syndromes subgroups. After 12 months of therapy 69% stayed on LTG therapy versus 89% on VPA, after 24 months 57% versus 83% respectively. VPA showed comparable efficacy in all IGE syndromes where LTG showed better efficacy in childhood and juvenile absence epilepsy than in juvenile myoclonic epilepsy. The shorter duration of treatment with LTG was due to lack of efficacy.
CONCLUSIONS: Our results show the superiority of VPA versus LTG treatment in idiopathic generalized epilepsy syndromes. (c) 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20167512     DOI: 10.1016/j.seizure.2010.01.014

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  7 in total

1.  Valproic Acid versus Lamotrigine as First-line Monotherapy in Newly Diagnosed Idiopathic Generalized Tonic -Clonic Seizures in Adults - A Randomized Controlled Trial.

Authors:  Vishal Prakash Giri; Om Prakash Giri; Farhan Ahmad Khan; Narendra Kumar; Ajay Kumar; Ataul Haque
Journal:  J Clin Diagn Res       Date:  2016-07-01

Review 2.  Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on once-daily lamotrigine.

Authors:  Linda Steinbaugh; Jerzy P Szaflarski
Journal:  Drug Des Devel Ther       Date:  2010-11-18       Impact factor: 4.162

Review 3.  Expert opinion: use of valproate in girls and women of childbearing potential with epilepsy: recommendations and alternatives based on a review of the literature and clinical experience-a European perspective.

Authors:  Manuel Toledo; Barbara Mostacci; Magdalena Bosak; Joanna Jedrzejzak; Rhys H Thomas; Javier Salas-Puig; Arnaud Biraben; Bettina Schmitz
Journal:  J Neurol       Date:  2020-04-01       Impact factor: 4.849

4.  A comprehensive review of the literature on epilepsy in selected countries in emerging markets.

Authors:  Mallik Angalakuditi; Nupur Angalakuditi
Journal:  Neuropsychiatr Dis Treat       Date:  2011-09-29       Impact factor: 2.570

5.  Choice of Antiepileptic Drugs in Idiopathic Generalized Epilepsy: UAE Experience.

Authors:  Taoufik Alsaadi; Haytham Taha; Fatema Al Hammadi
Journal:  Epilepsy Res Treat       Date:  2015-05-20

6.  Anticancer effects of valproic acid on oral squamous cell carcinoma via SUMOylation in vivo and in vitro.

Authors:  Zhijian Sang; Yang Sun; Hong Ruan; Yong Cheng; Xiaojun Ding; Youcheng Yu
Journal:  Exp Ther Med       Date:  2016-11-15       Impact factor: 2.447

7.  Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid.

Authors:  Rakel Brendsdal Forthun; Tanima Sengupta; Hanne Kim Skjeldam; Jessica Margareta Lindvall; Emmet McCormack; Bjørn Tore Gjertsen; Hilde Nilsen
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.